Filter Releases
Date Title and Summary View
Jun 24, 2014
FREMONT, Calif., June 24, 2014 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering price of $14.00 per share, which includes the exercis...
Jun 18, 2014
May 15, 2014
Feb 24, 2014
Jan 13, 2014
Oct 8, 2012
May 24, 2012
Apr 1, 2012
Aug 31, 2011
FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has closed a Series B preferred stock financing of $30.0 million. Participating in the Series B financing are previous investors in the Company, NEA, CMEA and certain individual investors, as well as a new investor, Amgen Ventures, LLC. The proceeds of the financing will b...
Aug 31, 2011
Page: First Previous
= add release to Briefcase